
Sign up to save your podcasts
Or


Rama El Hakim from the University of Ottawa speaks with Dr. Doug Coyle, Professor at the University of Ottawa in the School of Epidemiology and Public Health. Listen in to learn about Dr. Coyle's recent work in CJC Open, which determines that lifesaving drug Canakinumab needs a cost reduction of 91% to be feasible in Canada.
Learn more: https://med.uottawa.ca/epidemiology/people/coyle-doug
00:10 | Introduction
01:41 | Dr. Coyle's Current Research Focuses
03:37 | Applications to Other Healthcare Systems
08:14 | Is the suggested 91% price reduction of Canakinumab feasible?
10:05 | Translating this research to clinical settings
11:05 | Advice to the general public
14:52 | Wrap-Up
Soundtrack by Secret Ops. All rights reserved. Learn more:
https://cctrax.com/mystified/secret-ops
https://creativecommons.org/licenses/by/4.0/
By BEaTS Research RadioRama El Hakim from the University of Ottawa speaks with Dr. Doug Coyle, Professor at the University of Ottawa in the School of Epidemiology and Public Health. Listen in to learn about Dr. Coyle's recent work in CJC Open, which determines that lifesaving drug Canakinumab needs a cost reduction of 91% to be feasible in Canada.
Learn more: https://med.uottawa.ca/epidemiology/people/coyle-doug
00:10 | Introduction
01:41 | Dr. Coyle's Current Research Focuses
03:37 | Applications to Other Healthcare Systems
08:14 | Is the suggested 91% price reduction of Canakinumab feasible?
10:05 | Translating this research to clinical settings
11:05 | Advice to the general public
14:52 | Wrap-Up
Soundtrack by Secret Ops. All rights reserved. Learn more:
https://cctrax.com/mystified/secret-ops
https://creativecommons.org/licenses/by/4.0/

229,674 Listeners

113,121 Listeners

458 Listeners

16,525 Listeners